# OPKO Health, Inc. (OPK)

> Source: Nexqual · https://nexqual.com/OPK · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, OPKO Health, Inc. (OPK), nexqual.com/OPK" · informational, not investment advice.

**Price:** USD 1.61 (+17.52% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 1.37 · day 1.48–1.7 · 52w 0.98–1.75 · market cap $1.20B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $588M, net income -$72.9M (-12.4% margin), free cash flow -$134M (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 4.38 (range 3–8.5).
- Total return with dividends: 1Y +7.3% vs S&P 500 +18.1%; 5Y -56.7% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD -0.06, revenue estimate $137M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.77B | $1.00B | $863M | $713M | $607M | $588M |
| Gross profit | — | $288M | $318M | $219M | $206M | — |
| Operating income | $18.8M | -$226M | -$157M | -$152M | -$117M | -$48.3M |
| Net income | -$30.1M | -$328M | -$189M | -$53.2M | -$226M | -$72.9M |
| EPS (diluted) | -$0.05 | -$0.46 | -$0.25 | -$0.08 | -$0.30 | — |
| Free cash flow | $6.2M | -$120M | -$44.5M | -$208M | -$191M | -$134M |
| Gross margin | — | 28.7% | 36.8% | 30.6% | 33.9% | — |
| Operating margin | 1.1% | -22.5% | -18.2% | -21.3% | -19.3% | -8.2% |
| Net margin | -1.7% | -32.7% | -21.9% | -7.5% | -37.2% | -12.4% |
| Revenue growth | +23.6% | -43.4% | -14.0% | -17.4% | -14.9% | — |
| Cash + short-term investments | $135M | $153M | $95.9M | $427M | $364M | — |
| Total debt | $205M | $11.0M | $9.7M | $440M | $4.0M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 2.0x · EV/EBITDA 21.8x · EV/Sales 1.5x · P/B 1.0x · FCF yield -11.15% · Earnings yield -6.07% · Buyback yield (TTM) 3.88% · Net cash $298M · EV $904M

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 4.38 (low 3, high 8.5).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +7.3% | -56.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +7.4% | -15.4% |
| Volatility (annualized) | 55.0% | 57.1% |
| Max drawdown | -28.1% (Oct 2025→Mar 2026) | -81.5% (Dec 2021→Jan 2024) |

## Peers (Diagnostics & Research)
FRNM (Freenome, Inc.) USD 12.29 -2.81% · CSTL (Castle Biosciences, Inc.) USD 33.8 +2.80% · PSNL (Personalis, Inc.) USD 15.93 +0.50% · WGS (GeneDx Holdings Corp.) USD 70.22 +8.10% · NEO (NeoGenomics, Inc.) USD 17.25 +3.54% · FLGT (Fulgent Genetics, Inc.) USD 21.34 +1.33%

## More
Full page: https://nexqual.com/OPK · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt